3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Fulvestrant
4
ribociclib
2
palbociclib
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tivozanib
1
serabelisib
1
sapanisertib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Lomustine
1
Letrozole
1
Imlunestrant
1
Doxorubicin
1
Cetuximab
1
Carboplatin
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
STX-478
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled